Hefei National Lab for Physical Sciences at the Microscale and Centers for Biomedical Engineering, University of Science and Technology of China, Hefei, Anhui, 230027, China.
Hefei National Lab for Physical Sciences at the Microscale and Centers for Biomedical Engineering, University of Science and Technology of China, Hefei, Anhui, 230027, China.
Acta Biomater. 2021 Aug;130:473-484. doi: 10.1016/j.actbio.2021.05.033. Epub 2021 Jun 1.
Transdermal delivery is an attractive strategy for treating superficial tumors. However, the applications of existing transdermal systems have been limited by low transdermal efficiency and poor therapeutic outcomes. Here, we develop a transdermal nanoplatform (+)T-SiDs, based on superparamagnetic iron oxide core, surface-modified with cationic lipids, transdermal enhanced peptide TD, and 1,1'-dioctadecyl-3,3,3',3'-tetramethylindotricarbocyanine iodide (DiR), and loaded with doxorubicin. The (+)T-SiDs compositions enable MR/NIR dual-modal imaging guided synergistic chemo-photothermal therapy to superficial tumors treatment via transdermal delivery. The (+)T-SiDs exhibit good stability, efficient cellular uptake, pH/photothermal responsive drug release, and high photothermal conversion efficiency (47.45%). Importantly, the transdermal delivery of (+)T-SiDs is significantly enhanced by TD functionalization. In vivo MR/NIR imaging shows that the (+)T-SiDs exhibit high transdermal efficiency and specificity in localization to the tumor site. Moreover, in comparison with individual chemo- or photothermal therapies, the combination of chemo-photothermal therapy exhibits more efficient tumor inhibition effects. This work presents a new transdermal treatment nanoplatform for dual-modal imaging-guided chemo-photothermal therapy of superficial tumors, with efficient tumor eradication and low systemic toxicity thus offering strong potential for clinical adoption. STATEMENT OF SIGNIFICANCE: Transdermal delivery is an attractive strategy for treating superficial tumors. However, a highly efficient transdermal nanoplatform remains to be developed. Herein, we designed a multifunctional transdermal nanoplatform for dual-modal imaging-guided chemo-photothermal therapy of superficial tumors, comprised of a super-paramagnetic iron oxide (SPIO) nanoparticle, which can act as an MRI contrast agent and photothermal agent; a transdermal enhanced peptide (TD) and cationic lipids, which can accelerate skin penetration; and a NIR dye (DiR) and doxorubicin (DOX), which can achieve a synergistic enhanced chemo-photothermal therapy with NIR imaging ability. The transdermal nanoplatform achieved efficient tumor eradication and low systemic toxicity, thus offering strong potential for clinical adoption.
经皮给药是治疗浅表肿瘤的一种有吸引力的策略。然而，现有的经皮给药系统的应用受到经皮效率低和治疗效果差的限制。在这里，我们基于超顺磁性氧化铁核心，表面修饰阳离子脂质、经皮增强肽 TD 和 1,1'-二辛基-3,3,3',3'-四甲基吲哚碳菁碘化物（DiR），并负载多柔比星，开发了一种经皮纳米平台（+）T-SiDs。（+）T-SiDs 组成使 MR/NIR 双模式成像引导协同化学-光热治疗能够通过经皮给药治疗浅表肿瘤。（+）T-SiDs 表现出良好的稳定性、高效的细胞摄取、pH/光热响应药物释放和高光热转换效率（47.45%）。重要的是，TD 功能化显著增强了（+）T-SiDs 的经皮传递。体内 MR/NIR 成像显示，（+）T-SiDs 具有高经皮效率和对肿瘤部位的特异性定位。此外，与单独的化疗或光热治疗相比，化学-光热治疗的联合具有更有效的肿瘤抑制作用。这项工作提出了一种新的经皮治疗纳米平台，用于 MR/NIR 双模式成像引导的浅表肿瘤化学-光热治疗，具有高效的肿瘤消除和低系统毒性，因此具有很强的临床应用潜力。
经皮给药是治疗浅表肿瘤的一种有吸引力的策略。然而，仍需要开发一种高效的经皮纳米平台。在这里，我们设计了一种多功能经皮纳米平台，用于 MR/NIR 双模式成像引导的浅表肿瘤化学-光热治疗，该平台由超顺磁性氧化铁（SPIO）纳米颗粒组成，可作为 MRI 造影剂和光热剂；经皮增强肽（TD）和阳离子脂质，可加速皮肤渗透；以及近红外染料（DiR）和多柔比星（DOX），可实现具有近红外成像能力的协同增强化学-光热治疗。经皮纳米平台实现了高效的肿瘤消除和低系统毒性，因此具有很强的临床应用潜力。
